Abstract: The prognosis of advanced pancreatic cancer is extremely poor. According to clinical trials concerned with first-line systemic therapy， the median progression-free survival （PFS） was 5 months and median overall survival （OS） was less than one year. To those patients benefited from first-line regimen and with good performance status， can we switch the therapeutic modality into a single cytotoxic or target agent. It is so called “maintenance therapy”? As concerned to pancreatic cancer patients received radical resection， five-year survival rate was less than 25％ even adjuvant therapy completed. May maintenance therapy continue with adjuvant setting aimed to prolong disease-free survival? We combed these burning problems to be solved practically in order to provide clinical reference.